Pediatric-inspired Therapy compared to Allografting for Philadelphia Chromosome Negative XXXX in First Complete Remission.

@entity1 @entity3432 @entity8 @entity981 @entity3012 @entity1778
UNASSIGNED: For adults with Philadelphia chromosome negative (Ph-) @entity981 ( @entity981 ) in first complete remission ( @entity3432 ), allogeneic @entity8 ( @entity8 ) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable @entity1778 free survival in the absence of @entity8 . We compared 422 @entity8 recipients aged 18-50 years with Ph- @entity981 in @entity3432 reported to the CIBMTR with an age-matched concurrent cohort of 108 @entity981 @entity3432 @entity1 who received a Dana-Farber Consortium pediatric-inspired non- @entity8 regimen. At four years follow-up, incidence of relapse after @entity8 was 24% [95% C.I. 19-28] vs. 23% [95% C.I. 15-32] for the non- @entity8 ("chemo") cohort (p=0.97). Treatment-related mortality (TRM) was higher in the @entity8 cohort ( @entity8 37% [95% C.I. 31-42] vs. chemo 6% [95% C.I. 3 - 12], p<0.0001). DFS in the @entity8 cohort was 40% [95% C.I. 35-45] vs. 71% [95% C.I. 60-79] for chemo, p<0.0001. Similarly, @entity3012 favored chemo ( @entity8 45% [95% C.I. 40-50]) vs. chemo 73% [95% C.I. 63-81], p<0.0001). In multivariable analysis, the sole factor predictive of shorter @entity3012 was the administration of @entity8 (HR 3.12 [1.99 - 4.90], p<0.0001). For younger adults with @entity981 , pediatric-inspired chemotherapy had lower TRM, no increase in relapse, and superior overall survival compared to @entity8 . This article is protected by copyright. All rights reserved.
